NCT02867891View on ClinicalTrials.gov

Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial

CompletedOBSERVATIONAL

Enrollment

396

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Acute Myeloid Leukemia

All Listed Sponsors

lead

Robert Zeiser

OTHER

NCT02867891 - Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial | Biotech Hunter | Biotech Hunter